Cardiovascular
General versus Central Adiposity as Risk Factors for Cardiovascular-Related Outcomes in a High-Risk Population with Type 2 Diabetes: A Post Hoc Analysis of the REWIND Trial
Mar
Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79–132.
American Diabetes Association Professional Practice Committee. 8 obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2021;45:113–24.
Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol. 2006;35(1):83–92.
Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature. Eur J Clin Nutr. 2010;64(1):16–22.
Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab. 2010;95(4):1777–85.
Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9.
The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–95.
Carmienke S, Freitag MH, Pischon T, Schlattmann P, Fankhaenel T, Goebel H, et al. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur J Clin Nutr. 2013;67(6):573–85.
Gnatiuc L, Alegre-Díaz J, Wade R, Ramirez-Reyes R, Tapia-Conyer R, Garcilazo-Ávila A, et al. General and abdominal adiposity and mortality in Mexico city. Ann Intern Med. 2019;171(6):397–405.
Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–20.
Flegal KM, Graubard BI. Estimates of excess deaths associated with body mass index and other anthropometric variables. Am J Clin Nutr. 2009;89(4):1213–9.
Medina-Inojosa JR, Batsis JA, Supervia M, Somers VK, Thomas RJ, Jenkins S, et al. Relation of waist-hip ratio to long-term cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2018;121(8):903–9.
Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Waist-to-hip ratio and mortality in heart failure. Eur J Heart Fail. 2018;20(9):1269–77.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–9.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B. 1996;58(1):267–88.
Belsey DA, Kuh E, Welsch RE. Regression diagnostics: Identifying influential data and sources of collinearity. New York: John Wiley & Sons; 1980.
Staiano AE, Bouchard C, Katzmarzyk PT. BMI-specific waist circumference thresholds to discriminate elevated cardiometabolic risk in White and African American adults. Obes Facts. 2013;6(4):317–24.
Doehner W, Gerstein HC, Ried J, Jung H, Asbrand C, Hess S, et al. Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020;41(28):2668–77.
Lamelas P, Schwalm JD, Leong D, Jolly S, Mehta S, Bangdiwala S, et al. Varying effects of body mass index and mortality in different risk groups. Am J Cardiol. 2018;122(7):1155–60.
Piepoli MF, Corrà U, Veglia F, Bonomi A, Salvioni E, Cattadori G, et al. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the MECKI score research group. Eur J Heart Fail. 2016;18(5):545–53.
Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–13.
Glogner S, Rosengren A, Olsson M, Gudbjörnsdottir S, Svensson A-M, Lind M. The association between BMI and hospitalization for heart failure in 83 021 persons with type 2 diabetes: a population-based study from the Swedish national diabetes registry. Diabet Med. 2014;31(5):586–94.
Chaney E, Shaw A. Pathophysiology of Fluid Retention in Heart Failure. Contrib Nephrol. 2010;164:46–53.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596-646.
Lopez-Lopez JP, Cohen DD, Ney-Salazar D, Martinez D, Otero J, Gomez-Arbelaez D, et al. The prediction of metabolic syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. Cardiovasc Diabetol. 2021;20(1):68.
Parente EB, Harjutsalo V, Forsblom C, Groop P-H, on behalf of The FinnDiane Study Group. The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes a 16-year cohort study. Cardiovasc Diabetol. 2021;20(1):153.
Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12(1):38.
Hazewinkel A-D, Richmond RC, Wade KH, Dixon P. Mendelian randomization analysis of the causal impact of body mass index and waist-hip ratio on rates of hospital admission. Econ Hum Biol. 2022;44:101088.
Selvaraj S, Martinez EE, Aguilar FG, Kim K-YA, Peng J, Sha J, et al. Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study. Circ Cardiovasc Imaging. 2016. https://doi.org/10.1161/CIRCIMAGING.115.004396.
Piché M-E, Poirier P, Lemieux I, Després J-P. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61(2):103–13.
Ke J-F, Wang J-W, Lu J-X, Zhang Z-H, Liu Y, Li L-X. Waist-to-height ratio has a stronger association with cardiovascular risks than waist circumference, waist-hip ratio and body mass index in type 2 diabetes. Diabetes Res Clin Pract. 2022;183:109151.
Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.
Bando Y, Kanehara H, Aoki K, Hisada A, Toya D, Tanaka N. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Investig. 2012;3(2):170–4.
American Diabetes Association. 10 cardiovascular disease and risk management: standards of medical care in diabetes 2022. Diabetes Care. 2021;45:144-74. https://doi.org/10.2337/dc22-S010
